Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cagrilintide vs Liraglutide
An educational, source-based comparison of Cagrilintide and Liraglutide — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes
- • Investigational; not yet FDA-approved as monotherapy.
- • GI side effects similar to GLP-1 agonists.
A daily GLP-1 receptor agonist with a fatty-acid side chain that enables albumin binding and ~13-hour half-life. Mechanism mirrors semaglutide at shorter duration: enhanced glucose-dependent insulin release, slowed gastric emptying, and central appetite suppression.
- Type 2 diabetes (Victoza)
- Chronic weight management (Saxenda)
- Cardiovascular risk reduction in T2D
- • FDA-approved; requires prescription and physician oversight.
- • GI side effects, pancreatitis risk, gallbladder events.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cagrilintide | Cagrilintide plus semaglutide for obesity (Phase 2) | The Lancet | 2021 | Combination produced greater weight loss than either agent alone. |
| Liraglutide | Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER) | New England Journal of Medicine | 2016 | Significant reduction in major adverse cardiovascular events vs placebo. |
Side-effect & safety grid
- Investigational; not yet FDA-approved as monotherapy.
- GI side effects similar to GLP-1 agonists.
- FDA-approved; requires prescription and physician oversight.
- GI side effects, pancreatitis risk, gallbladder events.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cagrilintide vs Liraglutide — Key differences
- Class: Cagrilintide is classified as Metabolic · Amylin, while Liraglutide is Metabolic · Incretin.
- Primary research focus: Cagrilintide — weight management as monotherapy and combined with semaglutide (cagrisema); Liraglutide — type 2 diabetes (victoza).
- Tag: Weight loss vs Weight loss · Diabetes.